Glucosamine sulphate: an umbrella review of health outcomes

Veronese, Nicola and Demurtas, Jacopo and Smith, Lee and Reginster, Jean-Yves and Bruyère, Olivier and Beaudart, Charlotte and Honvo, Germain and Maggi, Stefania (2020) Glucosamine sulphate: an umbrella review of health outcomes. Therapeutic Advances in Musculoskeletal Disease, 12. pp. 1-12. ISSN 1759-7218

[img]
Preview
Text
Published Version
Available under the following license: Creative Commons Attribution Non-commercial.

Download (335kB) | Preview
[img] Text
Accepted Version
Restricted to Repository staff only
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (200kB) | Request a copy
Official URL: https://doi.org/10.1177/1759720X20975927

Abstract

BACKGROUND & AIMS: Glucosamine sulphate (GS) can be used as background therapy in people affected by knee osteoarthritis (OA). The knowledge regarding the efficacy and safety of GS is of importance since its use worldwide is increasing. Therefore, the present study aimed to map and grade the diverse health outcomes associated with GS using an umbrella review approach. METHODS: Medline, Cinhal and Embase databases were searched until 01st April 2020. An umbrella review of systematic reviews and meta-analyses of randomized controlled trials (RCTs) was carried out. The evidence from RCTs was graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) tool. RESULTS: From 140 articles returned, 11 systematic reviews, for a total of 21 outcomes (37 RCTs; 3,949 participants; almost all using 1,500 mg/day), were included. No systematic reviews/meta-analyses of observational studies were included. Regarding the findings of the meta-analyses, 9/17 outcomes were statistically significant, indicating that GS is more effective than placebo. A high certainty of evidence, as assessed by the GRADE, supported the use of GS (vs. placebo), in improving the Lequesne index, joint space width change, joint space width change after 3 years of follow-up, joint space narrowing and OA progression. No difference in terms of adverse effects was found between GS and placebo. In systematic reviews, GS was associated with a better glucose profile and a better physical function performance than placebo. CONCLUSIONS: GS, when used as prescription drug (i.e. crystalline glucosamine sulfate) at 1,500mg daily dosage, can positively affect the cartilage structure, reduce pain, improve function and glucose metabolism in people with knee OA, without having a greater incidence of adverse effects than placebo.

Item Type: Journal Article
Keywords: glucosamine sulphate, osteoarthritis, umbrella review
Faculty: Faculty of Science & Engineering
SWORD Depositor: Symplectic User
Depositing User: Symplectic User
Date Deposited: 04 Nov 2020 11:13
Last Modified: 20 Jan 2021 11:33
URI: https://arro.anglia.ac.uk/id/eprint/706019

Actions (login required)

Edit Item Edit Item